

**§ 868.2377 Apnea monitor.**

(a) *Identification.* An apnea monitor is a complete system intended to alarm primarily upon the cessation of breathing timed from the last detected breath. The apnea monitor also includes indirect methods of apnea detection such as monitoring of heart rate and other physiological parameters linked to the presence or absence of adequate respiration.

(b) *Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Apnea Monitors; Guidance for Industry and FDA.”

[67 FR 46852, July 17, 2002]

**§ 868.2380 Nitric oxide analyzer.**

(a) *Identification.* The nitric oxide analyzer is a device intended to measure the concentration of nitric oxide in respiratory gas mixtures during administration of nitric oxide.

(b) *Classification.* Class II. The special control for this device is FDA’s “Guidance Document for Premarket Notification Submissions for Nitric Oxide Administration Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer.”

[65 FR 14465, Mar. 3, 2000]

**§ 868.2385 Nitrogen dioxide analyzer.**

(a) *Identification.* The nitrogen dioxide analyzer is a device intended to measure the concentration of nitrogen dioxide in respiratory gas mixtures during administration of nitric oxide.

(b) *Classification.* Class II. The special control for this device is FDA’s “Guidance Document for Premarket Notification Submissions for Nitric Oxide Administration Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer.”

[65 FR 11465, Mar. 3, 2000]

**§ 868.2450 Lung water monitor.**

(a) *Identification.* A lung water monitor is a device used to monitor the trend of fluid volume changes in a patient’s lung by measuring changes in thoracic electrical impedance (resistance to alternating current) by means

of electrodes placed on the patient’s chest.

(b) *Classification.* Class III (premarket approval).

(c) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP for a device is required to be filed with the Food and Drug Administration on or before July 12, 2000, for any lung water monitor that was in commercial distribution before May 28, 1976, or that has, on or before July 12, 2000, been found to be substantially equivalent to a lung water monitor that was in commercial distribution before May 28, 1976. Any other lung water monitor device shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.

[47 FR 31142, July 16, 1982, as amended at 52 FR 17735, May 11, 1987; 65 FR 19834, Apr. 13, 2000]

**§ 868.2480 Cutaneous carbon dioxide (PcCO<sub>2</sub>) monitor.**

(a) *Identification.* A cutaneous carbon dioxide (PcCO<sub>2</sub>) monitor is a noninvasive heated sensor and a pH-sensitive glass electrode placed on a patient’s skin, which is intended to monitor relative changes in a hemodynamically stable patient’s cutaneous carbon dioxide tension as an adjunct to arterial carbon dioxide tension measurement.

(b) *Classification.* Class II (special controls). The special control for this device is FDA’s “Class II Special Controls Guidance Document: Cutaneous Carbon Dioxide (PcCO<sub>2</sub>) and Oxygen (PcO<sub>2</sub>) Monitors; Guidance for Industry and FDA.” See § 868.1(e) for the availability of this guidance document.

[54 FR 27160, June 28, 1989, as amended at 67 FR 76681, Dec. 13, 2002]

**§ 868.2500 Cutaneous oxygen (PcO<sub>2</sub>) monitor.**

(a) *Identification.* A cutaneous oxygen (PcO<sub>2</sub>) monitor is a noninvasive, heated sensor (e.g., a Clark-type polarographic electrode) placed on the patient’s skin that is intended to monitor relative changes in the cutaneous oxygen tension.

(b) *Classification.* Class II (special controls). The special control for this